What is CerFlux?
CerFlux is a pioneering biotechnology firm dedicated to transforming the standard of care in oncology through its Personalized Oncology Efficacy Test (POET). This innovative platform enables the simultaneous screening of multiple therapeutic agents against a patient's specific biopsy tissue, effectively bridging the gap between diagnostic testing and clinical application. By identifying the most efficacious treatment pathways within a one-week timeframe, CerFlux addresses the systemic inefficiencies of trial-and-error chemotherapy. The company serves a diverse ecosystem, including healthcare providers, payors, and pharmaceutical entities, by mitigating the financial and physical burdens associated with ineffective cancer treatments. Its market position is defined by a commitment to reducing healthcare costs while simultaneously improving patient outcomes through data-driven, individualized therapy selection.
How much funding has CerFlux raised?
CerFlux has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2021): $1M, investors not publicly disclosed
Key Investors in CerFlux
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CerFlux?
With this major strategic investment, CerFlux is poised to accelerate its clinical validation efforts and expand its footprint within the personalized medicine sector. The company is expected to leverage this capital to enhance its POET platform, potentially integrating advanced analytics to further refine treatment matching accuracy. As the firm transitions from its initial development phase toward broader commercial adoption, the focus will likely shift to establishing strategic partnerships with major oncology centers and pharmaceutical developers. By scaling its laboratory infrastructure and optimizing its diagnostic workflow, CerFlux aims to solidify its role as a critical component in the future of precision oncology, ultimately setting a new benchmark for how cancer therapies are evaluated and administered on a global scale.
See full CerFlux company page
